Table 3.
Effect of 10-Year CHD Risk on Lifetime Cost-Utility Ratio for 45-Year-Old Men
| Low (2.5%) Risk |
Low- Moderate (5.0%) Risk |
Moderate (7.5%) Risk |
High- Moderate (10%) Risk |
High (15%) Risk |
Very High (25%) Risk |
|
|---|---|---|---|---|---|---|
| Results for 45-Year-Old Men | ||||||
| Aspirin vs. no treatment | $5,714 | More effective, less costly | More effective, less costly | More effective, less costly | More effective, less costly | More effective, less costly |
| Aspirin+PPI vs. aspirin alone | $782,929 | $627,863 | $502,362 | $447,077 | $379,096 | $343,448 |
| Results for 65-Year-Old Men | ||||||
| Aspirin vs. no treatment | — | $11,039 | $3,634 | $50 | More effective, less costly | More effective, less costly |
| Aspirin+PPI vs. aspirin alone | — | $360,273 | $320,421 | $276,984 | $236,420 | $180,793 |
CHD = coronary heart disease; PPI = proton pump inhibitor